| Response to neoadjuvant chemotherapy | Relapse-free survival | |||||
---|---|---|---|---|---|---|---|
 | pCR | No pCR | P-value | No. of Patients (No. of events) | 3-year estimates | 95% CI | P-value |
All patients | 20 | 17 | Â | 42 (12) | 0.72 | 0.55-0.89 | Â |
Response to neoadjuvant chemotherapy | Â | Â | Â | Â | Â | Â | Â |
 pCR (grade 3) |  |  |  | 20 (4) | 0.73 | 0.52-0.93 | 0.764 |
 No pCR (grade 0~2) |  |  |  | 17 (5) | 0.86 | 0.67-1.04 |  |
Hormone receptors | Â | Â | Â | Â | Â | Â | Â |
 Positive | 8 | 14 | 0.009 | 25 (7) | 0.76 | 0.58-0.95 | 0.914 |
 Negative | 12 | 3 |  | 17 (5) | 0.69 | 0.42-0.95 |  |
HER2 copy numbers | Â | Â | Â | Â | Â | Â | Â |
 ≤ 2.0 | 1 | 6 | 0.019 | 8 (5) | 0.57 | 0.20-0.94 | 0.095 |
 > 2.0 | 19 | 11 |  | 34 (7) | 0.78 | 0.62-0.94 |  |
Wild-type HER2 mRNA | Â | Â | Â | Â | Â | Â | Â |
 < 400 | 8 | 9 | 0.208 | 20 (8) | 0.61 | 0.40-0.83 | 0.022 |
 ≥ 400 | 11 | 5 |  | 17 (2) | 0.92 | 0.76-1.07 |  |
∆16HER2 mRNA |  |  |  |  |  |  |  |
 < 4.5 | 5 | 8 | 0.020 | 17 (5) | 0.72 | 0.50-0.93 | 0.314 |
 ≥ 4.5 | 15 | 4 |  | 20 (5) | 0.75 | 0.53-0.96 |  |
Percentages of ∆16HER2 mRNA |  |  |  |  |  |  |  |
 < 2.4% | 17 | 11 | 0.581 | 31 (6) | 0.79 | 0.63-0.94 | 0.039 |
 ≥ 2.4% | 5 | 1 |  | 6 (4) | 0.50 | 0.10-0.90 |  |
PIK3CA | Â | Â | Â | Â | Â | Â | Â |
 Wild-type | 18 | 14 | 0.498 | 36 (9) | 0.79 | 0.64-0.94 | 0.171 |
 Mutated | 2 | 3 |  | 6 (3) | 0.42 | −0.02-0.85 |  |
PIK3CA | Â | Â | Â | Â | Â | Â | Â |
 Wild-type + Normal + Loss + UPD | 16 | 9 | 0.08 | 28 (6) | 0.85 | 0.70-1.01 | 0.041 |
 Mutated + Gain | 4 | 8 |  | 14 (6) | 0.56 | 0.29-0.83 |  |
PTEN | Â | Â | Â | Â | Â | Â | Â |
 Normal + Gain + UPD | 20 | 12 | 0.009 | 37 (11) | 0.73 | 0.56-0.89 | 0.705 |
 Loss | 0 | 5 |  | 5 (1) | 0.80 | 0.45-1.15 |  |
INPP4B | Â | Â | Â | Â | Â | Â | Â |
 Normal + Gain + UPD | 17 | 16 | 0.373 | 36 (8) | 0.79 | 0.64-0.94 | 0.095 |
 Loss | 3 | 1 |  | 6 (4) | 0.50 | 0.10-0.90 |  |
PI3KCA , PTEN, INPP4B | Â | Â | Â | Â | Â | Â | Â |
 No aberrations* | 14 | 6 | 0.086 | 22 (4) | 0.81 | 0.60-1.01 | 0.195 |
 Aberrations** | 6 | 11 |  | 20 (8) | 0.67 | 0.45-0.89 |  |
DEK | Â | Â | Â | Â | Â | Â | Â |
 Normal | 13 | 14 | 0.236 | 28 (5) | 0.88 | 0.75-1.01 | 0.006 |
 Gain | 7 | 3 |  | 14 (7) | 0.44 | 0.14-0.75 |  |
FGFR1 | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss + UPD | 17 | 9 | 0.035 | 29 (9) | 0.75 | 0.48-0.86 | 0.641 |
 Gain | 3 | 8 |  | 13 (3) | 0.92 | 0.76-1.07 |  |
CCND1 | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss | 11 | 12 | 0.33 | 25 (4) | 0.84 | 0.68-1.01 | 0.043 |
 Gain | 9 | 5 |  | 17 (8) | 0.58 | 0.33-0.84 |  |
FOXA1 | Â | Â | Â | Â | Â | Â | Â |
 Normal + UPD | 15 | 13 | 0.917 | 30 (6) | 0.80 | 0.64-0.96 | 0.012 |
 Gain | 5 | 4 |  | 12 (6) | 0.60 | 0.29-0.91 |  |
CDH3 | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss + UPD | 19 | 14 | 0.217 | 37 (8) | 0.79 | 0.64-0.94 | 0.009 |
 Gain | 1 | 3 |  | 5 (4) | 0.40 | −0.03-0.83 |  |
BIRC5 | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss + UPD | 14 | 13 | 0.659 | 27 (5) | 0.82 | 0.66-0.98 | 0.005 |
 Gain | 6 | 4 |  | 15 (7) | 0.56 | 0.25-0.88 |  |
MYBL2 | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss | 18 | 10 | 0.028 | 30 (7) | 0.80 | 0.64-0.96 | 0.053 |
 Gain | 2 | 7 |  | 12 (5) | 0.58 | 0.24-0.91 |  |
AIB1 | Â | Â | Â | Â | Â | Â | Â |
 Normal + Loss | 18 | 11 | 0.063 | 31 (7) | 0.81 | 0.65-0.96 | 0.017 |
 Gain | 2 | 6 |  | 11 (5) | 0.52 | 0.15-0.89 |  |